GLPwatch
[SGLT2 inhibitor or GLP-1 receptor agonist in a patient with type 2 diabetes and cardiovascular disease ?]
Rev Med Liege · 2018
Last updated 2026-05-28Two types of diabetes drugs—SGLT2 inhibitors like empagliflozin and GLP-1 receptor agonists like liraglutide—have been shown to reduce major heart-related events and death in people with type 2 diabetes and high heart disease risk. While both drug classes work differently, they may offer complementary benefits, leaving doctors to decide which one to prescribe based on a patient’s specific needs.
AI summary of the abstract below.
| Journal | Rev Med Liege, 2018 |
|---|---|
| Citations | 0 |
| Relative citation ratio | 0.00 |
| NIH percentile | 0 |
| Molecules | — |
| Conditions studied | Type 2 Diabetes, Cardiovascular Risk Reduction |
Abstract
Two classes of antidiabetic agents have shown a cardiovascular and renal protection in patients with type 2 diabetes and high cardiovascular risk. Empagliflozin, a sodium-glucose cotransporter type 2 (SGLT2) inhibitor, and liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, were granted a reduction of major cardiovascular events and mortality after the positive results of EMPA-REG OUTCOME and LEADER outcome trials, respectively. Protection mechanisms most probably differ between the two pharmacological classes and are perhaps complementary. The question that may arise in clinical practice is to know which drug should be selected between these two options in a patient with type 2 and established cardiovascular disease, before considering a potential combination. The aim of this article is to discuss about the best therapeutic choice according to the patient individual profile and the specificities of each molecule.
Verbatim abstract via PubMed 29388411 ↗